MiniMed Group (NASDAQ:MMED) Price Target Raised to $28.00 at Bank of America

MiniMed Group (NASDAQ:MMED) had its target price boosted by analysts at Bank of America from $24.00 to $28.00 in a report released on Wednesday, MarketBeat Ratings reports. The firm presently has a “buy” rating on the stock. Bank of America‘s target price would indicate a potential upside of 24.89% from the stock’s previous close.

MMED has been the topic of a number of other research reports. BTIG Research lifted their price target on shares of MiniMed Group from $25.00 to $28.00 and gave the company a “buy” rating in a report on Tuesday. Wells Fargo & Company dropped their price target on shares of MiniMed Group from $26.00 to $22.00 and set an “overweight” rating on the stock in a research note on Thursday, June 4th. Benchmark reiterated a “buy” rating on shares of MiniMed Group in a research note on Thursday, June 4th. UBS Group initiated coverage on MiniMed Group in a research note on Tuesday, July 28th. They set a “buy” rating and a $25.00 price objective on the stock. Finally, Piper Sandler reaffirmed a “neutral” rating and issued a $16.00 price target on shares of MiniMed Group in a report on Thursday, June 4th. Thirteen research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $22.46.

MiniMed Group Stock Performance

MMED opened at $22.42 on Wednesday. MiniMed Group has a one year low of $10.65 and a one year high of $22.74. The business’s fifty day moving average price is $17.65. The stock has a market capitalization of $6.31 billion and a P/E ratio of -32.97.

MiniMed Group (NASDAQ:MMED) last released its quarterly earnings results on Wednesday, June 3rd. The company reported ($0.68) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.22) by ($0.46). The firm had revenue of $837.00 million during the quarter. MiniMed Group’s revenue for the quarter was up 15.6% compared to the same quarter last year. Equities analysts anticipate that MiniMed Group will post 0.66 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in the business. BlackRock Inc. lifted its holdings in shares of MiniMed Group by 7,527.5% during the second quarter. BlackRock Inc. now owns 1,996,489 shares of the company’s stock valued at $29,848,000 after purchasing an additional 1,970,314 shares during the last quarter. J. Goldman & Co LP acquired a new stake in MiniMed Group during the second quarter valued at $12,412,000. Readystate Asset Management LP bought a new stake in MiniMed Group in the second quarter worth approximately $4,400,000. Bank of America Corp DE boosted its stake in shares of MiniMed Group by 377.0% during the 2nd quarter. Bank of America Corp DE now owns 238,819 shares of the company’s stock worth $3,570,000 after acquiring an additional 188,756 shares in the last quarter. Finally, Freestone Grove Partners LP acquired a new position in MiniMed Group in the 2nd quarter valued at $1,745,000.

MiniMed Group News Roundup

Here are the key news stories impacting MiniMed Group this week:

• Positive Sentiment: MiniMed reported fiscal Q1 2027 net sales of $843 million, up 17% year over year, with organic U.S. sales growth accelerating to 13% and international sales rising 18% as reported. Earnings per share also exceeded analyst expectations. MiniMed Delivers Strong Start to Fiscal Year 2027 with U.S. Growth Acceleration
• Positive Sentiment: Management raised its fiscal 2027 organic revenue-growth guidance, signaling confidence that recent momentum can continue. The company also said its product pipeline is progressing ahead of schedule, including FDA submission plans for MiniMed Fit™, CE Mark progress for MiniMed Flex™, completion of enrollment in the Vivera™ FCL U.S. pivotal trial, and IDE approval for a next-generation extended-wear sensor. MiniMed Group Releases Q1 2027 Financial Results
• Positive Sentiment: BTIG Research raised its price target to $28 from $25 and maintained a “buy” rating, reflecting expectations for further upside based on the company’s growth outlook. MiniMed Group Price Target Increase
• Neutral Sentiment: The earnings call highlighted the quarter’s performance and pipeline developments, giving investors additional detail on the company’s operating outlook. MiniMed Group Q1 2027 Earnings Call Transcript
• Negative Sentiment: The consensus broker price target is $21.62, below the stock’s recent quoted level, suggesting that some analysts see limited near-term upside despite the improved operating results. MiniMed Group Receives Consensus Target Price

About MiniMed Group

We are a scaled global medical technology company that develops, manufactures, and markets a comprehensive suite of solutions for the management of diabetes. Since our founding more than 40 years ago, we have pioneered groundbreaking innovation and served the needs of our customers across the globe in service of our mission to make every day a better day for people with diabetes. Today, we are the only player in the market that commercializes all parts of an integrated diabetes management system.